Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: Final ENESTcmr randomized trial results

Leukemia

Volumn 31, Issue 11, 2017, Pages 2529-2531

  Hughes, T P ^a   Leber, B ^b   Cervantes, F ^c   Spector, N ^d   Pasquini, R ^e   Clementino, N C D ^f   Schwarer, A P ^g   Dorlhiac Llacer, P E ^h   Mahon, F X ⁱ   Rea, D ^j   Guerci Bresler, A ^k   Kamel Reid, S ^l   Bendit, I ^h   Acharya, S ^m   Glynos, T ⁿ   Dalal, D ⁿ   Branford, S ^o   Lipton, J H ^p  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BARCELONA   (Spain)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^g ALFRED HOSPITAL   (Australia)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k CHU NANCY BRABOIS   (France)

^l TORONTO GENERAL HOSPITAL   (Canada)

^m Novartis Healthcare Pvt Ltd   (India)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^p UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

BCR ABL1 GENE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; LIVER FAILURE; MAJOR CLINICAL STUDY; MORTALITY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DEEP MOLECULAR RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; METABOLISM;

ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 85032620270     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.247     Document Type: Letter

References (12)

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic mye-loid leukemia: 2013. Blood 2013; 122: 872-884.
2. National Comprehensive Cancer Network 2017. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. 2017; v2.2017.
3. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553-561.
4. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835-1840.
5. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
6. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
7. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123-1132.
8. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080-7085.
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
10. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044-1054.
11. Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NCD et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 2014; 124: 729-736.
12. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016; 128: 17-23.